VIR BIOTECHNOLOGY INC VIR
ASignal's systematic analysis rates VIR as Neutral.
Reflects the latest available analysis · analyzed Nov 11, 2026
The case on VIR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong technical momentum with RSI near overbought levels
- MACD above signal line with expanding histogram indicating strengthening uptrend
- Price trading above 20-day and 50-day moving averages
- Low debt-to-equity ratio of 0.10x indicating strong financial health
- High cash position with total cash of $458.36M providing runway
- Negative profit and net margins with net margin at -61.03%
- Negative operating cash flow of $-141.02M and free cash flow of $-81.92M
- Negative EV/EBITDA and forward P/E suggesting unprofitable outlook
- Absence of Reddit mentions indicating low retail investor interest
- Extremely high operating margin of 55,669.15% likely due to accounting anomalies or one-time factors
See the full verdict on VIR
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VIR
Most investors never get a second opinion, let alone several. ASignal runs VIR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.